Trials / Completed
CompletedNCT03210532
Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telmisartan + Amlodipine + Rosuvastatin | Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo |
| DRUG | Telmisartan + Amlodipine | Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo |
| DRUG | Telmisartan + Rosuvastatin | Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo |
Timeline
- Start date
- 2016-10-07
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2017-07-07
- Last updated
- 2018-02-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03210532. Inclusion in this directory is not an endorsement.